Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

View All

Feb 23, 2021 • 7:30 AM EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update

Feb 18, 2021 • 6:30 AM EST

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

Jan 29, 2021 • 2:45 PM EST

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

January 2021

View Presentation

Fourth Quarter and Year End 2020 Financial Results Conference Call

View Event View All

FY 2020

Fiscal Year Ended Dec 31, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080